Brian C Baumann1, Jiwei He2, Wei-Ting Hwang2, Kai N Tucker1, Justin E Bekelman1, Harry W Herr3, Seth P Lerner4, Thomas J Guzzo5, S Bruce Malkowicz5, John P Christodouleas6. 1. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Urology, Baylor College of Medicine, Houston, Texas. 5. Department of Urology, University of Pennsylvania, Philadelphia, Pennsylvania. 6. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: christojo@uphs.upenn.edu.
Abstract
PURPOSE: To inform prospective trials of adjuvant radiation therapy (adj-RT) for bladder cancer after radical cystectomy, a locoregional failure (LF) risk stratification was proposed. This stratification was developed and validated using surgical databases that may not reflect the outcomes expected in prospective trials. Our purpose was to assess sources of bias that may affect the stratification model's validity or alter the LF risk estimates for each subgroup: time bias due to evolving surgical techniques; trial accrual bias due to inclusion of patients who would be ineligible for adj-RT trials because of early disease progression, death, or loss to follow-up shortly after cystectomy; bias due to different statistical methods to estimate LF; and subgrouping bias due to different definitions of the LF subgroups. METHODS AND MATERIALS: The LF risk stratification was developed using a single-institution cohort (n=442, 1990-2008) and the multi-institutional SWOG 8710 cohort (n=264, 1987-1998) treated with radical cystectomy with or without chemotherapy. We evaluated the sensitivity of the stratification to sources of bias using Fine-Gray regression and Kaplan-Meier analyses. RESULTS: Year of radical cystectomy was not associated with LF risk on univariate or multivariate analysis after controlling for risk group. By use of more stringent inclusion criteria, 26 SWOG patients (10%) and 60 patients from the single-institution cohort (14%) were excluded. Analysis of the remaining patients confirmed 3 subgroups with significantly different LF risks with 3-year rates of 7%, 17%, and 36%, respectively (P<.01), nearly identical to the rates without correcting for trial accrual bias. Kaplan-Meier techniques estimated higher subgroup LF rates than competing risk analysis. The subgroup definitions used in the NRG-GU001 adj-RT trial were validated. CONCLUSIONS: These sources of bias did not invalidate the LF risk stratification or substantially change the model's LF estimates.
PURPOSE: To inform prospective trials of adjuvant radiation therapy (adj-RT) for bladder cancer after radical cystectomy, a locoregional failure (LF) risk stratification was proposed. This stratification was developed and validated using surgical databases that may not reflect the outcomes expected in prospective trials. Our purpose was to assess sources of bias that may affect the stratification model's validity or alter the LF risk estimates for each subgroup: time bias due to evolving surgical techniques; trial accrual bias due to inclusion of patients who would be ineligible for adj-RT trials because of early disease progression, death, or loss to follow-up shortly after cystectomy; bias due to different statistical methods to estimate LF; and subgrouping bias due to different definitions of the LF subgroups. METHODS AND MATERIALS: The LF risk stratification was developed using a single-institution cohort (n=442, 1990-2008) and the multi-institutional SWOG 8710 cohort (n=264, 1987-1998) treated with radical cystectomy with or without chemotherapy. We evaluated the sensitivity of the stratification to sources of bias using Fine-Gray regression and Kaplan-Meier analyses. RESULTS: Year of radical cystectomy was not associated with LF risk on univariate or multivariate analysis after controlling for risk group. By use of more stringent inclusion criteria, 26 SWOG patients (10%) and 60 patients from the single-institution cohort (14%) were excluded. Analysis of the remaining patients confirmed 3 subgroups with significantly different LF risks with 3-year rates of 7%, 17%, and 36%, respectively (P<.01), nearly identical to the rates without correcting for trial accrual bias. Kaplan-Meier techniques estimated higher subgroup LF rates than competing risk analysis. The subgroup definitions used in the NRG-GU001 adj-RT trial were validated. CONCLUSIONS: These sources of bias did not invalidate the LF risk stratification or substantially change the model's LF estimates.
Authors: Michael Froehner; Vladimir Novotny; Manfred P Wirth; Sabine Brookman-May; Atiqullah Aziz; Matthias May Journal: Cancer Date: 2014-07-12 Impact factor: 6.860
Authors: John P Christodouleas; Brian C Baumann; Jiwei He; Wei-Ting Hwang; Kai N Tucker; Justin E Bekelman; Catherine M Tangen; Seth P Lerner; Thomas J Guzzo; S Bruce Malkowicz; Harry Herr Journal: Cancer Date: 2014-01-03 Impact factor: 6.860
Authors: Brian C Baumann; Thomas J Guzzo; Jiwei He; Stephen M Keefe; Kai Tucker; Justin E Bekelman; Wei-Ting Hwang; David J Vaughn; S Bruce Malkowicz; John P Christodouleas Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-28 Impact factor: 7.038
Authors: Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Mohamed S Zaghloul; John P Christodouleas; Andrew Smith; Ahmed Abdallah; Hany William; Hussein M Khaled; Wei-Ting Hwang; Brian C Baumann Journal: JAMA Surg Date: 2018-01-17 Impact factor: 14.766
Authors: Brian C Baumann; Walter R Bosch; Amit Bahl; Alison J Birtle; Rodney H Breau; Amarnath Challapalli; Albert J Chang; Ananya Choudhury; Sia Daneshmand; Ali El-Gayed; Adam Feldman; Steven E Finkelstein; Thomas J Guzzo; Serena Hilman; Ashesh Jani; S Bruce Malkowicz; Constantine A Mantz; Viraj Master; Anita V Mitra; Vedang Murthy; Sima P Porten; Pierre M Richaud; Paul Sargos; Jason A Efstathiou; Libni J Eapen; John P Christodouleas Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-07 Impact factor: 7.038
Authors: Paul Sargos; Brian C Baumann; Libni J Eapen; Amit Bahl; Vedang Murthy; Guilhem Roubaud; Mathieu Orré; Jason A Efstathiou; Shahrokh Shariat; Stephane Larré; Pierre Richaud; John P Christodouleas Journal: Transl Androl Urol Date: 2016-10
Authors: Brian C Baumann; Paul Sargos; Libni J Eapen; Jason A Efstathiou; Ananya Choudhury; Amit Bahl; Vedang Murthy; Leslie K Ballas; Valérie Fonteyne; Pierre M Richaud; Mohamed S Zaghloul; John P Christodouleas Journal: Bladder Cancer Date: 2017-01-27
Authors: Benjamin W Fischer-Valuck; Jeff M Michalski; Nandita Mitra; John P Christodouleas; Todd A DeWees; Eric Kim; Zachary L Smith; Gerald L Andriole; Vivek Arora; Arnold Bullock; Ruben Carmona; Robert S Figenshau; Robert L Grubb; Thomas J Guzzo; Eric M Knoche; S Bruce Malkowicz; Ronac Mamtani; Russell K Pachynski; Bruce J Roth; Mohamed S Zaghloul; Hiram A Gay; Brian C Baumann Journal: Cancer Med Date: 2019-05-22 Impact factor: 4.452